Author

C. Alamillo-Ferrer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

C. I. Wells· 2 shared C. R. M. Asquith· 2 shared D. H. Drewry· 2 shared G. J. Tizzard· 2 shared T. Laitinen· 2 shared A. D. Axtman· 1 shared A. Goenka· 1 shared A. Poso· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

C. I. Wells

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Discovery and Optimization of Narrow Spectrum Inhibitors of Tousled Like Kinase 2 (TLK2) Using Quantitative Structure Activity Relationships

C. R. M. Asquith, M. P. East, T. Laitinen, C. Alamillo-Ferrer, E. Hartikainen, C. I. Wells, A. D. Axtman, D. H. Drewry, G. J. Tizzard, A. Poso, T. M. Willson, G. L. Johnson

The paper identifies and optimizes narrow-spectrum TLK2 inhibitors using QSAR analysis and structural studies.

bioRxiv · Dec 28, 2023Pharmacology & Toxicology

Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug resistant gliomas

D. M. Tiek, B. Erdogdu, R. Razaghi, L. Jin, N. Sadowski, C. Alamillo-Ferrer, J. R. Hogg, B. R. Haddad, D. H. Drewry, C. I. Wells, J. E. Pickett, X. Song, A. Goenka, B. Hu, S. L. Goldlust, , R. B. Riggins

This study identifies guanine mutations in TMZ-resistant gliomas that disrupt G4 structures and splice sites, creating vulnerabilities targeted by G4 stabilizers and splicing inhibitors.

bioRxiv · Nov 21, 2021Cancer Biology

Design and evaluation of novel 4-anilinoquinolines and quinazolines as EGFR inhibitors in lung cancer and chordoma

C. R. M. Asquith, K. A. Maffuid, T. Laitinen, C. D. Torrice, G. J. Tizzard, C. Alamillo-Ferrer, K. M. Koshlap, D. J. Crona, W. Zuercher

The paper designs and evaluates novel 4-anilinoquinolines and quinazolines as EGFR inhibitors, identifying a potent compound for lung cancer and chordoma treatment.

bioRxiv · Feb 11, 2019 · PreprintPharmacology & Toxicology